Literature DB >> 15004025

Differential regulatory and compensatory responses in hematopoiesis/erythropoiesis in alpha- and beta-globin hemizygous mice.

Hugues Beauchemin1, Marie-José Blouin, Marie Trudel.   

Abstract

Characterization of hematopoiesis/erythropoiesis in thalassemias from multipotent primitive cells to mature erythrocytes is of fundamental importance and clinical relevance. We investigated this process in alpha- and beta-globin hemizygous mice, lacking the two adult tandemly organized genes from either the alpha- or beta-globin locus. Although both mice backcrossed on a homogeneous background exhibited similar reduced red blood cell (RBC) survival, beta-globin hemizygous mice had less severe reticulocyte loss and globin chain imbalance, suggesting an apparently milder thalassemia than for alpha-globin hemizygous mice. In contrast, however, beta-globin hemizygous mice displayed a more marked perturbation of hematologic parameters. Quantification of erythroid precursor subpopulations in marrow and spleen of beta-globin hemizygous mice showed more severely impaired maturation from the basophilic to orthochromatophilic erythroblasts and substantial loss of these late precursors probably as a consequence of a greater susceptibility to an excess of free alpha-chain than beta-chain. Hence, only erythroid precursors exhibiting stochastically moderate chain imbalance would escape death and mature to reticulocyte/RBC stage, leading to survival and minimal loss of reticulocytes in the beta-globin hemizygous mice. Furthermore, in response to the ineffective erythropoiesis in beta-globin hemizygous mice, a dynamic compensatory hematopoiesis was observed at earlier differentiation stage as evidenced by a significant increase of erythroid progenitors (erythroid colony-forming units approximately 100-fold) as well as of multipotent primitive cells (day 12 spleen colony-forming units approximately 7-fold). This early compensatory mechanism was less pronounced in alpha-globin hemizygous mice. The expansion of multipotent primitive and potentially stem cell populations, taken together with ineffective erythropoiesis and increased reticulocyte/RBC destruction could confer major cumulative advantage for gene targeting/bone marrow transplantation. Therefore, this study not only corroborated the strong potential effectiveness of transplantation for thalassemic hematopoietic therapy but also demonstrated the existence of a differential regulatory response for alpha- and beta-thalassemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004025     DOI: 10.1074/jbc.M309989200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.

Authors:  Ilaria V Libani; Ella C Guy; Luca Melchiori; Raffaella Schiro; Pedro Ramos; Laura Breda; Thomas Scholzen; Amy Chadburn; YiFang Liu; Margrit Kernbach; Bettina Baron-Lühr; Matteo Porotto; Maria de Sousa; Eliezer A Rachmilewitz; John D Hood; M Domenica Cappellini; Patricia J Giardina; Robert W Grady; Johannes Gerdes; Stefano Rivella
Journal:  Blood       Date:  2008-05-14       Impact factor: 22.113

2.  Poly(C)-Binding Protein Pcbp2 Enables Differentiation of Definitive Erythropoiesis by Directing Functional Splicing of the Runx1 Transcript.

Authors:  Louis R Ghanem; Andrew Kromer; Ian M Silverman; Xinjun Ji; Matthew Gazzara; Nhu Nguyen; Gabrielle Aguilar; Massimo Martinelli; Yoseph Barash; Stephen A Liebhaber
Journal:  Mol Cell Biol       Date:  2018-07-30       Impact factor: 4.272

3.  Correction of murine hemoglobinopathies by prenatal tolerance induction and postnatal nonmyeloablative allogeneic BM transplants.

Authors:  William H Peranteau; Satoshi Hayashi; Osheiza Abdulmalik; Qiukan Chen; Aziz Merchant; Toshio Asakura; Alan W Flake
Journal:  Blood       Date:  2015-06-29       Impact factor: 22.113

4.  The autophagy-activating kinase ULK1 mediates clearance of free α-globin in β-thalassemia.

Authors:  Christophe Lechauve; Julia Keith; Eugene Khandros; Stephanie Fowler; Kalin Mayberry; Abdullah Freiwan; Christopher S Thom; Paola Delbini; Emilio Boada Romero; Jingjing Zhang; Irene Motta; Heather Tillman; M Domenica Cappellini; Mondira Kundu; Mitchell J Weiss
Journal:  Sci Transl Med       Date:  2019-08-21       Impact factor: 17.956

5.  Imbalanced globin chain synthesis determines erythroid cell pathology in thalassemic mice.

Authors:  Kanitta Srinoun; Saovaros Svasti; Worrakavee Chumworathayee; Jim Vadolas; Phantip Vattanaviboon; Suthat Fucharoen; Pranee Winichagoon
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

6.  Transferrin therapy ameliorates disease in beta-thalassemic mice.

Authors:  Huihui Li; Anne C Rybicki; Sandra M Suzuka; Leni von Bonsdorff; William Breuer; Charles B Hall; Z Ioav Cabantchik; Eric E Bouhassira; Mary E Fabry; Yelena Z Ginzburg
Journal:  Nat Med       Date:  2010-01-24       Impact factor: 53.440

7.  UCP2 modulates cell proliferation through the MAPK/ERK pathway during erythropoiesis and has no effect on heme biosynthesis.

Authors:  Alvaro Elorza; Brigham Hyde; Hanna K Mikkola; Sheila Collins; Orian S Shirihai
Journal:  J Biol Chem       Date:  2008-08-07       Impact factor: 5.157

8.  Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme.

Authors:  Nestor W Meza; Maria E Alonso-Ferrero; Susana Navarro; Oscar Quintana-Bustamante; Antonio Valeri; Maria Garcia-Gomez; Juan A Bueren; Jose M Bautista; Jose C Segovia
Journal:  Mol Ther       Date:  2009-09-15       Impact factor: 11.454

9.  Evidence for a bigenic chromatin subdomain in regulation of the fetal-to-adult hemoglobin switch.

Authors:  Hugues Beauchemin; Marie Trudel
Journal:  Mol Cell Biol       Date:  2008-12-29       Impact factor: 4.272

10.  Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia.

Authors:  Yi Kong; Suiping Zhou; Anthony J Kihm; Anne M Katein; Xiang Yu; David A Gell; Joel P Mackay; Kazuhiko Adachi; Linda Foster-Brown; Calvert S Louden; Andrew J Gow; Mitchell J Weiss
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.